WHO Obesity Guidelines: New Era for Weight-Loss Drugs

The World Health Organization has issued its inaugural guidelines for treating obesity, acknowledging it as a chronic and relapsing medical condition rather than a cosmetic issue. The recommendations suggest using weight-loss therapies, such as semaglutide and tirzepatide, for long-term treatment in adults, excluding pregnant women. These medications should be coupled with intensive behavioral therapies, including lifestyle counseling and meal replacements, though evidence for these co-interventions is of low certainty.

Globally, equitable access to these drugs is a significant hurdle, compounded by supply shortages and high prices. Current production capacity can only serve about 10% of the estimated 100 million individuals living with obesity worldwide. India is actively working on its own diagnostic and treatment guidelines, with experts emphasizing the prioritization of adults with a BMI over 35 or those with a BMI over 30 who have severe obesity-related co-morbidities.

Efforts are underway to establish a new obesity management ecosystem, particularly in India, by integrating screening and follow-up into primary health centers. There is also a critical need to combat misconceptions that view obesity solely as a lifestyle issue. Robust procurement and regulatory systems are essential to ensure a safe and uninterrupted supply of GLP-1 medicines, addressing the challenges of falsified products and paving the way for more accessible treatments.